Six guidelines to navigate the Aduhelm controversy and (hopefully) help patients with Mild Cognitive Impairment and early-stage Alzheimer’s Disease

By Kaiser Health News | October 13, 2021

The approval of a con­tro­ver­sial new drug for Alzheimer’s dis­ease, Aduhelm, is shin­ing a spot­light on mild cog­ni­tive impair­ment — prob­lems with mem­o­ry, atten­tion, lan­guage or oth­er cog­ni­tive tasks that exceed changes expect­ed with nor­mal aging. After ini­tial­ly indi­cat­ing that Aduhelm could be pre­scribed to any­one with demen­tia, the Food and Drug Admin­is­tra­tion now spec­i­fies that…

Read More

On cognitive reframing and biases, stress, mental health tech, Aduhelm backlash, Britney Spears, and more

By SharpBrains | August 31, 2021

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing this time nine sci­en­tif­ic reports and indus­try devel­op­ments to help pro­mote life­long brain and men­tal health. #1. To low­er stress lev­els and improve prob­lem-solv­ing, prac­tice cog­ni­tive refram­ing instead of vent­ing “… vent­ing like­ly doesn’t soothe anger as much as aug­ment it. That’s because encour­ag­ing peo­ple to…

Read More

Veterans Affairs won’t cover Biogen’s new “Alzheimer’s drug” given concerns over safety and lack of evidence

By SharpBrains | August 16, 2021

VA Health Sys­tem Won’t Cov­er Biogen’s Alzheimer’s Drug (The Wall Street Jour­nal): The Depart­ment of Vet­er­ans Affairs won’t cov­er Bio­gen Inc.’s new Alzheimer’s drug, the lat­est rebuke of the con­tro­ver­sial treat­ment since it was approved ear­li­er this sum­mer. The VA decid­ed not add the drug, called Aduhelm, to its for­mu­la­ry list of avail­able med­i­cines because…

Read More

The new frontier in neurocognitive monitoring and dementia screening: the Apple Watch

By SharpBrains | January 12, 2021

Bio­gen to Launch Pio­neer­ing Study to Devel­op Dig­i­tal Bio­mark­ers of Cog­ni­tive Health Using Apple Watch and iPhone (press release): Bio­gen Inc. (Nas­daq: BIIB) today announced a new vir­tu­al research study, in col­lab­o­ra­tion with Apple, to inves­ti­gate the role Apple Watch and iPhone could play in mon­i­tor­ing cog­ni­tive per­for­mance and screen­ing for decline in cog­ni­tive health…

Read More

Study: Actual, sustained practice–not mere knowledge–is needed to harness neuroplasticity and improve cognition over time

By SharpBrains | September 14, 2020

Lifestyle improve­ments may lessen cog­ni­tive decline (Wiley): ” … 19 indi­vid­u­als old­er than 65 years of age who were expe­ri­enc­ing cog­ni­tive decline were ran­dom­ized to a con­trol group or an inter­ven­tion group for 8 weeks. The con­trol group received online infor­ma­tion relat­ed to demen­tia and lifestyle risk fac­tors, Mediter­ranean diet, phys­i­cal activ­i­ty, and cog­ni­tive engagement.…

Read More

Anticholinergic drugs found to significantly increase risk of cognitive decline, especially among those with Alzheimer’s Disease biomarkers or genetic predisposition

By SharpBrains | September 11, 2020

Com­mon Class of Drugs Linked to Increased Risk of Alzheimer’s Dis­ease (UC San Diego release): A team of sci­en­tists, led by researchers at Uni­ver­si­ty of Cal­i­for­nia San Diego School of Med­i­cine, report that a class of drugs used for a broad array of con­di­tions, from aller­gies and colds to hyper­ten­sion and uri­nary incon­ti­nence, may be…

Read More